References
- Accardo AP, Pensiero S, Perissutti P. Saccadic analysis for early identification of neurological involvement in Gaucher disease. Annals of the New York Academy of Sciences 2005; 1039: 503–507
- Beutler E. Enzyme replacement in Gaucher disease. PLoS medicine 2004; 1: e21
- Beutler E. Gaucher disease: Multiple lessons from a single gene disorder. Acta Paediatrica. Supplementum 2006; 95: 103–109
- Beutler E, Kuhl W, Vaughan LM. Failure of alglucerase infused into Gaucher disease patients to localize in marrow macrophages. Molecular Medicine 1995; 1: 320–324
- Butters TD, Dwek RA, Platt FM. Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. Glycobiology 2005; 15: 43R–52R
- Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, Platt F, Butters T, Dwek R, Moyses C, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000; 355: 1481–1485
- Elstein D, Guedalia J, Doniger GM, Simon ES, Antebi V, Arnon Y, Zimran A. Computerized cognitive testing in patients with type I Gaucher disease: Effects of enzyme replacement and substrate reduction. Genetics in Medicine 2005; 7: 124–130
- Elstein D, Hollak C, Aerts JM, van Weely S, Maas M, Cox TM, Lachmann RH, Hrebicek M, Platt FM, Butters TD, et al. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. Journal of Inherited Metabolic Disease 2004; 27: 757–766
- Grosman ME, Elias MM, Comin EJ, Rodriguez Garay EA. Alterations in renal function induced by aflatoxin B1 in the rat. Toxicology and Applied Pharmacology 1983; 69: 319–325
- Lebel E, Dweck A, Foldes AJ, Golowa Y, Itzchaki M, Zimran A, Elstein D. Bone density changes with enzyme therapy for Gaucher disease. Journal of Bone and Mineral Metabolism 2004; 22: 597–601
- Mankin HJ, Trahan CA, Barnett NA, Laughead J, Bove CM, Pastores GM. A questionnaire study for 128 patients with Gaucher disease. Clinical Genetics 2006; 69: 209–217
- Mercimek-Mahmutoglu S. Unpublished results; data presented at SSIEM. Amsterdam. 2004
- Pastores GM, Barnett NL, Bathan P, Kolodny EH. A neurological symptom survey of patients with type I Gaucher disease. Journal of Inherited Metabolic Disease 2003; 26: 641–645
- Pastores GM, Barnett NL, Kolodny EH. An open-label, noncomparative study of miglustat in type I Gaucher disease: Efficacy and tolerability over 24 months of treatment. Clinical Therapeutics 2005; 27: 1215–1227
- Perretti A, Parenti G, Balbi P, Titomanlio L, Marcantonio L, Iapoce M, Frascogna AR, Andria G, Santoro L. Study of multimodal evoked potentials in patients with type 1 Gaucher's disease. Journal of Child Neurology 2005; 20: 124–128
- Platt FM, Jeyakumar M, Andersson U, Heare T, Dwek RA, Butters TD. Substrate reduction therapy in mouse models of the glycosphingolipidoses. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 2003; 358: 947–954
- Priestman DA, Platt FM, Dwek RA, Butters TD. Imino sugar therapy for type 1 Gaucher disease. Glycobiology 2000; 10: iv–vi
- Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases. Journal of Pharmaceutical Sciences 2005; 94: 1259–1276
- Rudzki Z, Okon K, Machaczka M, Rucinska M, Papla B, Skotnicki AB. Enzyme replacement therapy reduces Gaucher cell burden but may accelerate osteopenia in patients with type I disease—A histological study. European Journal of Haematology 2003; 70: 273–281
- Schiffmann R, Mankin H, Dambrosia JM, Xavier RJ, Kreps C, Hill SC, Barton NW, Rosenthal DI. Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells, Molecules and Diseases 2002; 28: 288–296
- Sidransky E. Gaucher disease and parkinsonism. Molecular Genetics and Metabolism 2005; 84: 302–304
- Yang SK, Hsieh YY, Chang WC, Huang JD. Enantioselectivity of microsomal and cytosolic esterases in rat intestinal mucosa. Drug Metabolism and Disposition 1992; 20: 719–725
- Zimran A, Elstein D. Gaucher disease and the clinical experience with substrate reduction therapy. Philosophical transactions of the Royal Society of London. Series B, Biological Sciences 2003; 358: 961–966